Researchers and “advocates for all vaccine research today launched yet another effort to increase funding and coordination,” ScienceInsider reports.
In this report from the Center for Strategic and International Studies, released ahead of the GAVI Alliance pledging conference, authors Lisa Carty, J. Stephen Morrison, Margaret Reeves, and Amanda Glassman write, “Its many achievements notwithstanding, GAVI still needs a strategic approach in the coming years if it is to deepen…
GlaxoSmithKline and drug company Crucell, a division of Johnson & Johnson, will collaborate with the PATH Malaria Vaccine Initiative to test a second-generation malaria vaccine “within the next couple of months,” Reuters reports.
The GAVI Alliance has appealed to donors for $3.7 billion to be pledged during an upcoming conference despite announcements by several major pharmaceutical companies to lower the prices of their vaccines for childhood diseases, the Associated Press/Washington Post reports (6/6).
Several pharmaceutical companies have pledged to lower the prices of vaccines against childhood illnesses ahead of the GAVI Alliance conference in London next week, the Guardian reports (Quinn, 6/6).
In his Washington Post column, Michael Gerson writes about British Prime Minister David Cameron’s approach to budget cuts.
“Considering its wealth, the U.S. spends relatively little on humanitarian aid that can make an enormous difference in the lives of millions of people â€“ and in the perception of the U.S. around the world. Nothing this nation could do with $450 million would surpass the good accomplished with a vaccination pledge to GAVI,” according to a Detroit Free Press editorial, which calls for President Barack Obama to provide $450 million over three years for the GAVI Alliance (6/1).
The appointment of Dutch pharmaceutical company Crucell, recently acquired by Johnson & Johnson, to the board of the GAVI Alliance is “sparking concerns over conflicts of interest and demands for tougher competition to reduce prices,” the Financial Times reports.
Where Is Global Health On The G8 Agenda?: As the G8 summit began in Deauville, France, on Thursday, David Olson, the council’s director of policy communications,Â wrote on the Global Health Council’s “Blog 4 Global Health” that “global health is nowhere visible on the agenda,” which “is in striking contrast to…
The May 26 issue of Nature explores vaccines, which the journal says “are responsible for some of the world’s greatest public health triumphs.” Though new vaccines for deadly diseases have been developed in the past 10 years, and more are in development, “funding is tight, and unfounded doubts about the safety of vaccines persist.” The issue features stories on polio, measles, HIV/AIDS, tuberculosis and malaria, as well as issues surrounding vaccine rejection and hysteria about risk (5/26).